Last reviewed · How we verify
NCT06331793: Algocare
Pulsed Electromagnetic Fields for Analgesia Post Mastectomy
NA trial testing Active AlgoCare in Female Breast Cancer in 160 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | European Institute of Oncology |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 160 |
| Start date | 9 May 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Active AlgoCare
- Non-active AlgoCare
Conditions studied
- Female Breast Cancer — all drugs for Female Breast Cancer →
- Post Operative Pain — all drugs for Post Operative Pain →
Sponsor
European Institute of Oncology
Who can join
18 and older, female only, with Female Breast Cancer or Post Operative Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study aim is to test AlgoCare, a device that uses the technology PEMF (Pulsed ElectroMagnetic Fields) for the treatment of postoperative pain in oncological breast surgery, in order to demonstrate that the use of Algocare in the postoperative period allows for a reduction in pain intensity in terms of Numerical Rating Scale (NRS) score and use of analgesic drugs.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.
Li K, Guo B, Gu J, Ta N, et al · · 2025 · cited 8× · PMID 39759851 · DOI 10.1016/j.mtbio.2024.101375
Verify or expand the search:
- PubMed search for NCT06331793
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Female Breast Cancer
Currently open trials in the same condition.
- NCT06696378 — Melatonin Supplementation and Exercise Program in Breast Cancer Women · NA · recruiting
- NCT06618690 — Exercise Program on Pain, Physical Function, and Quality of Life in Breast Cancer Survivors · NA · active not recruiting
- NCT06144164 — A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With B · Phase 3 · recruiting
- NCT05586256 — Ultra-hypofractionated Radiotherapy in Breast Cancer Patients · recruiting
Other European Institute of Oncology trials
Trials by the same sponsor.
- NCT07374809 — IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER · NA · not yet recruiting
- NCT07429851 — CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07508319 — Role of the Immune System in Preventing Laryngeal Cancer · recruiting
- NCT07180693 — Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06331793 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European Institute of Oncology
- Last refreshed: 26 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06331793.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing